TabsDetailsBasic DetailsDate: Monday, November 12, 2012Type: PublicationMedical Product: aliskiren, angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitorHealth Outcome(s): angioedemaDescription: This article describes a Mini-Sentinel protocol-based one-time assessment of the risk of angioedema associated with new use of drugs that act on the renin-angiotensin-aldosterone system (RAAS), including angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and aliskiren. Read More Materials: Archives of Internal Medicine, Volume 172, Issue 20, November 2012, Pages 1582-1589, DOI: 10.1001/2013Additional InformationInformationTime Period: 2001 - 2010Population / Cohort: All individuals 18 years of age or olderData Source(s): Mini-Sentinel Distributed Database (MSDD)Related Assessment(s): Drugs that Act on the Renin-Angiotensin-Aldosterone System (Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Aliskiren) & AngioedemaContributorsAuthor(s): Sengwee Toh ScD; Marsha E. Reichman PhD; Monika Houstoun PharmD; Mary Ross Southworth PharmD; Xiao Ding PhD; Adrian F. Hernandez MD; Mark Levenson PhD; Lingling Li PhD; Carolyn McCloskey MD, MPH; Azadeh Shoaibi MS, MHS; Eileen Wu PharmD; Gwen Zornberg MD, MS, ScD; Sean Hennessy PharmD, PhDCorresponding Author: S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. Email: darren_toh@harvardpilgrim.org
